• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Announcements July 12, 2021

SRI International’s Parijat Bhatnagar receives DARPA award to continue groundbreaking research into engineered immunity

SRI International researcher Parijat Bhatnagar, Ph.D., has been awarded the Director’s Fellowship Option of the Defense Advanced Research Projects Agency (DARPA) Young Faculty Award (YFA). The prestigious award provides additional funds for Bhatnagar and his team to continue developing cells that can be stimulated via extracorporeal devices to treat viral infections. Only top performers among the first phase of DARPA YFA awardees receive the Director’s Fellowship Option.

During the first phase of the project, the SRI team developed a genetic circuitry that can be used to trigger cells – via a stimulus delivered from outside the body – to regulate the synthesis of proteins with desired therapeutic properties inside the body. This is important because many proteins are toxic when systemically delivered in high quantities, but therapeutic when tightly regulated. Additionally, the team de-risked the feasibility of their approach by demonstrating that the cells they stimulate can synthesize proteins with antiviral effects.

With the Director’s Fellowship funding, the team intends to advance their cellular platform as a therapeutic that can universally target multiple viruses. This will involve integrating different technology components to generate cells that can be remotely activated to regulate production of targeted antiviral proteins. The team will also advance the technology by implementing the genetic circuits into an appropriate cellular “chassis” that will enable its human use.

“This is a potentially transformative approach for controlling and eliminating biological threats,” said Bhatnagar. “As we saw with COVID-19, the process of developing countermeasures for each new biological threat is time- and resource-intensive. If and when we face the next emerging infection, our cell-based platform could be immediately available, potentially saving lives by stopping a pandemic before it begins.

“It is an honor that DARPA has trusted our team to continue this work, which could protect our troops against unknown biological threats. It speaks volumes about the strength of our team and what we have accomplished together,” Bhatnagar added.

The objective of the DARPA YFA program is to identify and engage rising stars, and to expose them to DoD needs and DARPA’s program-development process. The program provides funding, mentoring, and industry and DoD contacts to awardees early in their careers so that they may develop their research ideas in the context of national security needs.

Bhatnagar’s research is also supported by the National Institutes of Health (NIH) Director’s New Innovator Award administered by the National Institute of Biomedical Imaging and Bioengineering (NIBIB); and the Innovative Molecular Analysis Technologies (IMAT) program, a niche program within the National Cancer Institute (NCI), which supports potentially transformative next-generation technologies for targeting cancer.

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2023 SRI International
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}